Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed its provisional Q4 and FY2024 consolidated financial results via fair disclosure, reporting Q4 revenue of KRW 1.256T (+17.04% YoY) and operating profit of KRW 325.7B (-6.94% YoY). Full-year 2024 cumulative revenue reached KRW 4.547T (+23.08% YoY) with operating profit of KRW 1.320T (+18.53% YoY).
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Provisional Operating Results Based on Consolidated Financial Statements (Fair Disclosure)
- Period Covered: Q4 2024 and FY2024 Cumulative (Jan 1, 2024 – Dec 31, 2024)
- Consolidated Financial Summary (Unit: KRW million, %):
- Revenue:
- Q4 2024: KRW 1,256,439 million (+5.84% QoQ, +17.04% YoY)
- FY2024 Cumulative: KRW 4,547,322 million (+23.08% YoY)
- Operating Profit:
- Q4 2024: KRW 325,664 million (-3.81% QoQ, -6.94% YoY)
- FY2024 Cumulative: KRW 1,320,052 million (+18.53% YoY)
- Profit Before Income Tax:
- Q4 2024: KRW 374,015 million (+28.53% QoQ, +5.15% YoY)
- FY2024 Cumulative: KRW 1,370,052 million (+22.33% YoY)
- Net Profit:
- Q4 2024: KRW 321,494 million (+21.56% QoQ, +10.60% YoY)
- FY2024 Cumulative: KRW 1,083,316 million (+26.31% YoY)
- Net Profit Attributable to Owners of Parent:
- Q4 2024: KRW 321,494 million (+21.56% QoQ, +10.60% YoY)
- FY2024 Cumulative: KRW 1,083,316 million (+26.31% YoY)
- Revenue:
- Information Provision Details:
- Provider: IR Team
- Target Audience: Domestic and foreign investors, press, etc.
- Date & Time: January 22, 2025
- Other Important Details:
- Related materials will be published on the company website (http://www.samsungbiologics.com).
- The figures were prepared prior to completion of the external audit, thus subject to change depending on audit results.
- Related Disclosure: January 08, 2025: Advance Notice of Financial Results Announcement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Provisional Earnings Release and Upcoming Annual/Audit Report Filings
This disclosure provides notice of Samsung Biologics’ provisional consolidated financial results for Q4 and FY2024 via fair disclosure.
Because these numbers were prepared prior to completion of the external audit, checking the finalized figures in the upcoming periodic report (Annual Report/Audit Report) and IR materials on the official website is essential.
Relevant details can be verified in the subsequent audit report, annual report filing, and the IR section of the company’s official website.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
